Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo SmithKline U.S. Marketing Could Reach 250,000 MDs In One Week

Executive Summary

The combined Glaxo SmithKline U.S. sales force would be able to call on 250,000 physicians during the first week of a major product launch, the companies told a Jan. 17 London press briefing on their proposed merger.

You may also be interested in...



Novartis, Bristol To Share Zelmac; Novartis Opts For Partnership, Not Merger

Novartis' agreement with Bristol Myers-Squibb to co-promote the irritable bowel syndrome treatment Zelmac (tegaserod) accomplishes one objective of the Swiss company's attempts to grow via a merger in the U.S.

Novartis, Bristol To Share Zelmac; Novartis Opts For Partnership, Not Merger

Novartis' agreement with Bristol Myers-Squibb to co-promote the irritable bowel syndrome treatment Zelmac (tegaserod) accomplishes one objective of the Swiss company's attempts to grow via a merger in the U.S.

Novartis Zelmac Co-Promotion Is Possibility, Firm Indicates

Novartis may consider a co-promotion partner for the irritable bowel syndrome therapy Zelmac (tegaserod) in the U.S., CEO Daniel Vasella indicated during an Aug. 21 conference call with analysts.

Related Content

UsernamePublicRestriction

Register

PS035480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel